



Document to Content Management: A Paradigm Change

DIA DRM SIAC – Content Re-Use

Donald Palmer, RAC

Assoc. Director, Regulatory Knowledge &
Information Management

June 21, 2012

Continuous Improvement




“Do you know that 87.166253% of all statistics claim a precision of results that is not justified by the method employed?”

- Unknown Statistician

Agenda

- **Why Move to Content Management?**
- **Re-Use & Content Management**
- **Tracking & Metrics**
- **Summary**




Why Move to Content Mgmt?

- **Labeling**
 - ◆ Core Data Sheet mapped to Package Labeling
- **Global Dossier Re-Use**
 - ◆ Global Dossier – similar content, different dossiers
- **Module 3 - CMC**
 - ◆ Granularity – same content, different sized documents
- **Health Authority Q & A, Correspondence**
 - ◆ Track Qs & As by Content
 - ◆ Track Qs & As by Health Authority


Consistency of Information

Labeling: Core Data Sheet

(example)



Consistency of Translation



Global Dossier

Marketing application in initial countries

(example Module 3)

Europe

- EU 3.2.P Drug Product
 - P.1 Description and Composition of the Drug Product
 - P.2 Pharmaceutical Development
 - P.3.1 Manufacturer(s) of Drug Product
 - P.3.2 Batch Formula for Drug Product
 - P.3.3 Description of Manufacturing Process and Process Controls
 - P.3.4 Controls of Critical Steps and Intermediates for Drug Product
 - P.3.5 Process Validation and/or Evaluation for Drug Product
 - P.4.1 Specifications for Excipients
 - P.4.5 Excipients of Human or Animal Origin
 - P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - P.5.4 Batch Analyses for Drug Product
 - P.5.6 Justification of Specifications for Drug Product
 - P.7 Container Closure System for Drug Product
 - P.7 Specification for Blister
 - P.8.1 Stability Summary for Drug Product
 - P.8.1 Stability Conclusion for Drug Product
 - P.8.2 Post-approval Stability Protocol and Stability Commitment
 - P.8.3 Stability Data for Drug Product

Upload to eCTD

Canada

- Canada 3.2.P Drug Product
 - P.1 Description and Composition of the Drug Product
 - P.2 Pharmaceutical Development
 - CA P.3.1 Manufacturer(s) of Drug Product
 - P.3.2 Batch Formula for Drug Product
 - P.3.3 Description of Manufacturing Process and Process Controls
 - P.3.4 Controls of Critical Steps and Intermediates for Drug Product
 - P.3.5 Process Validation and/or Evaluation for Drug Product
 - P.4.1 Specifications for Excipients
 - P.4.5 Excipients of Human or Animal Origin
 - P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - P.5.4 Batch Analyses for Drug Product
 - P.5.6 Justification of Specifications for Drug Product
 - CA P.7 Container Closure System for Drug Product
 - P.7 Specification for Blister
 - P.8.1 Stability Summary for Drug Product
 - CA P.8.1 Stability Conclusion for Drug Product
 - P.8.2 Post-approval Stability Protocol and Stability Commitment
 - P.8.3 Stability Data for Drug Product

Upload to eCTD

USA

- US 3.2.P Drug Product
 - US P.1 Description and Composition of the Drug Product
 - P.2 Pharmaceutical Development
 - US P.3.1 Manufacturer(s) of Drug Product
 - P.3.2 Batch Formula for Drug Product
 - P.3.3 Description of Manufacturing Process and Process Controls
 - P.3.4 Controls of Critical Steps and Intermediates for Drug Product
 - US P.3.5 Process Validation and/or Evaluation for Drug Product
 - P.4.1 Specifications for Excipients
 - P.4.5 Excipients of Human or Animal Origin
 - US P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - US P.5.4 Batch Analyses for Drug Product
 - US P.5.6 Justification of Specifications for Drug Product
 - US P.7 Container Closure System for Drug Product
 - US P.7 Specification for Bottle
 - US P.7 Manufacturer for Bottle
 - US P.8.1 Stability Summary for Drug Product
 - US P.8.1 Stability Conclusion for Drug Product
 - US P.8.2 Post-approval Stability Protocol and Stability Commitment
 - US P.8.3 Stability Data for Drug Product

Upload to eCTD

Global Dossier

Marketing application in subsequent countries (example Module 3)

International

- International 3.2.P Drug Product
 - IQD P.1 Description and Composition of the Drug Product
 - IQD P.2 Pharmaceutical Development
 - IQD P.3.1 Manufacturer(s) of Drug Product
 - P.3.2 Batch Formula for Drug Product
 - IQD P.3.3 Description of Manufacturing Process and Process Controls
 - IQD P.4.1 Specifications for Excipients
 - P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - IQD P.7 Container Closure System for Drug Product
 - P.7 Specification for Blister
 - P.8.1 Stability Summary for Drug Product
 - IQD P.8.1 Stability Conclusion for Drug Product
 - IQD P.8.3 Stability Data for Drug Product

ASEAN

- ASEAN 3.2.P Drug Product
 - P.1 Description and Composition of the Drug Product
 - ASEAN P.2 Pharmaceutical Development
 - ASEAN P.3.1 Batch Formula for Drug Product
 - ASEAN P.3.2 Description of Manufacturing Process and Process Control
 - ASEAN P.3.3 Control of Critical Steps and Intermediates
 - ASEAN Process Validation Annex 1
 - P.3.4 Controls of Critical Steps and Intermediates for Drug Product
 - P.4.1 Specifications for Excipients
 - ASEAN P.4.3 Excipients of Human or Animal Origin
 - P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - P.5.4 Batch Analyses for Drug Product
 - P.5.6 Justification of Specifications for Drug Product
 - P.7 Container Closure System for Drug Product
 - P.7 Specification for Blister
 - ASEAN Stability Annex 1
 - P.8.1 Stability Summary for Drug Product
 - P.8.1 Stability Conclusion for Drug Product
 - P.8.2 Post-approval Stability Protocol and Stability Commitment
 - P.8.3 Stability Data for Drug Product

China

- China CTA Item 10.2 Drug Product
 - P.5.1 Specifications
 - P.5.2 Analytical Procedure Description
 - P.5.2 Analytical Procedure Assay
 - P.5.2 Analytical Procedure Dissolution
 - P.5.3 Validation of Analytical Procedure for Assay
 - P.5.3 Validation of Analytical Procedure for Dissolution
 - P.5.4 Batch Analyses


Different
organisation
(as 'Items')

References
only to Ph Eur

Different numbering
Additional documents

Granularity

Module 3 – CMC



- EU 3.2.P Drug Product
 - P.1 Description and Composition of the Drug Product
 - P.2 Pharmaceutical Development
 - P.3.1 Manufacturer(s) of Drug Product
 - P.3.2 Batch Formula for Drug Product
 - P.3.3 Description of Manufacturing Process and Process Controls
 - P.3.4 Controls of Critical Steps and Intermediates for Drug Product
 - P.3.5 Process Validation and/or Evaluation for Drug Product
 - P.4.1 Specifications for Excipients
 - P.4.5 Excipients of Human or Animal Origin
 - P.5.1 Specification(s) for Drug Product
 - P.5.2 Analytical Procedure for Description
 - P.5.2 Analytical Procedure for Assay
 - P.5.2 Analytical Procedure for Dissolution
 - P.5.3 Validation of Analytical Procedures for Assay
 - P.5.3 Validation of Analytical Procedures for Dissolution
 - P.5.4 Batch Analyses for Drug Product
 - P.5.6 Justification of Specifications for Drug Product
 - P.7 Container Closure System for Drug Product
 - P.7 Specification for Blister
 - P.8.1 Stability Summary for Drug Product
 - P.8.1 Stability Conclusion for Drug Product
 - P.8.2 Post-approval Stability Protocol and Stability Commitment
 - P.8.3 Stability Data for Drug Product


Dossier as a virtual document

Common Technical Document topic





Further granularity*

* Allowed by ICH M4 “granularity annex”

Health Authority Q & A, Correspondence



Original Qs from
Health Authority



Clarify Qs from
Health Authority




Continuous Improvement




Agenda

- Why Move to Content Management?
- Re-Use & Content Management
- Tracking & Metrics
- Summary




- **Technical Manuals vs Submission Documents**
 - ◆ Tech Manuals include highly re-useable content
 - ◆ Submission Documents less re-useable content

- **Copy&Paste Re-Use vs Tracking Re-Use**
 - ◆ Re-Use via Copy&Paste loses tracking
 - ◆ Need Re-Use as traceable content



- 14

Re-Use: Tech Manuals vs Submission Docs




- **Submission documents have low re-use**
 - ♦ Few updates to same parts (Mod 3 main exception)
 - ♦ Content re-use mostly re-use of same sections to different documents, not strictly hierarchic

What could using Structured Authoring mean?


- **Re-usability (quality and consistency):**
 - ◆ Not caught out by changes that have implications on other documents' content
 - ◆ More efficient generation of Module 2.3 Quality Overall Summary
 - ◆ Establishment of databases for common information
 - ◆ Eliminate transcription errors
- **Potential M3 examples:**
 - ◆ 3.2.S and 3.2.P flow diagrams, specifications → Module 2.3
 - ◆ Container closure specification → many eCTD applications
 - ◆ Manufacturing site addresses → many eCTD applications
 - ◆ Facilities and Equipment → many eCTD applications
 - ◆ Chemical structures → CTA (IB, IMPD), MAA (M2.3, M3)

Easy Copy & Paste: No Traceability




- No Traceability of Content (except in Author's head)
- If changes made to 'Paste' side, no ability to later check if correct except via manual review

Tagged Copy & Paste: With Traceability



- **Traceability of Content can be determined**
 - ◆ Time and Date Stamp
 - ◆ Hand-off Metrics
- **Content within tags can be:**
 - ◆ Used for regulatory & compliance purposes
 - ◆ Used for quality check purposes

Health Authority Q & A, Correspondence



Continuous Improvement



Agenda

- Why Move to Content Management?
- Re-Use & Content Management
- Tracking & Metrics
- Summary



Tracking & Metrics

- **Registration (incl. Q&A & Correspondence)**
- **Labeling**
- **Global Dossier & Module Re-Use**
- **Quality Component**
- **Metrics Component (Improvement)**

Ensuring compliance today

Submission Lifecycle Information Management

- **Events** track the outcome of submissions
- **Outgoing package** records which documents were sent to which country
- Monitor if submission has been
 - ◆ Dispatched, submitted, approved, withdrawn, divested
- Maintain supply links
- View data from different perspectives



**Relies on
manual input**

Global Dossier

What might XML offer to applicants?

♦ Tracking:

- ♦ Reference links – update M3 content and flag for M2.3
- ♦ Track at content level instead of document level
 - By approval in 40+ countries, can have territorial variation *
- ♦ Track submissions by country
 - With XML tags can drag and drop a file on an Event to automatically recognize metadata for strength, product, dosage form, manufacturer

Tracking Changes: Manual Processes

How is Change Tracked?

- ◆ Author holds changes and change reasons in head
- ◆ Meeting Minutes of discussions?
- ◆ What about External / Contract Authors?


How is Content Re-Use Tracked?

- ◆ Author knows where content 'copied' from
- ◆ How has content been changed when re-used?


How is Tracking Captured?

- ◆ Manual Entry into Spreadsheets
- ◆ Manual Entry into Applications (DataBase)


Tracking: Protocol to Study Report Lifecycle



Tracking & Metrics: Labeling - (Manual Entry)



Tracking & Metrics: Labeling - (Manual Entry)



Tracking Changes: Automated Processes


How is Change Tracked?

- ◆ Tagged content changes automatically tracked through authoring workflow (internal & external)
- ◆ Tagged content, comments & edits, automatically tracked through review workflow (internal & external)


How is Content Re-Use Tracked?

- ◆ Re-Use automatically tracked through tagged content and versions
- ◆ Changed, Re-Used content automatically tracked via tagging and versions – still needs manual review for changes

Tracking: Protocol to Study Report Lifecycle




Tracking & Metrics: Labeling - (Automated Entry)



Tracking and Metrics


- **Tracking for Management**
 - ◆ Simple Tracking – Content Structured Templates
- **Metrics For Improvement**
 - ◆ Manual collection of metrics is time consuming and error-prone
 - ◆ Ongoing Metrics gathering requires Automation
- **Workflow Automation**
 - ◆ Ongoing Metrics gathering requires Automation
- **Quality Traceability**
 - ◆ Traceability required to include Quality Component

Continuous Improvement



Summary:

Moving to Content Management



- Information needs to be managed at the Content level
- Re-Use is helpful – requires Content level management
- Tracking Content & Re-Use is better
- Tracking Content needs to be Automated – Workflows
- Auto-Tracking Content provides Metrics for Continuous Improvement

Continuous Improvement



“There are three kinds of mathematicians; those who can count and those who can't.”
Anonymous